Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke

Stroke

Volumn 30, Issue 5, 1999, Pages 993-996

  Saxena, Ritu ^a   Wijnhoud, Annemarie D ^a   Carton, Herwig ^b   Hacke, Werner ^c   Kaste, Markku ^d   Przybelski, Robert J ^e   Stern, Kathleen N ^e   Koudstaal, Peter J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Blood substitutes; Hemoglobins; Safety; Stroke, acute; Stroke, ischemic

Indexed keywords

ACETYLSALICYLIC ACID; DIASPIRIN CROSSLINKED HEMOGLOBIN; HEPARIN; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; BRAIN EDEMA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; PANCREAS INSUFFICIENCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 0032921865     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.5.993     Document Type: Article

References (19)

1. Cole DJ, Schell RM, Przybelski RJ, Drummond JC, Bradley K. Focal cerebral ischemia in rats: effect of hemodilution with alpha-alpha cross-linked hemoglobin on CBF. J Cereb Blood Flow Metab. 1992;12: 971-976.
2. Bowes MP, Burhop KE, Zivin JA. Diaspirin cross-linked hemoglobin improves neurological outcome following reversible but not irreversible CNS ischemia in rabbits. Stroke. 1994;25:2253-2257.
3. Wise GR. Vasopressor-drug therapy for complications of cerebral arteriography. N Engl J Med. 1970;282:610-612.
4. Rordorf G, Cramer SC, Efird JT, Schwamm LH, Buonanno F, Koroshetz WJ. Pharmacological elevation of blood pressure in acute stroke: clinical effects and safety. Stroke. 1997;28:2133-2138.
5. Azari M, Rohn K, Picken J. Diaspirin crosslinked hemoglobin (DCLHb): characterization of the process and the product manufactured under GMP requirements for clinical studies. Artif Cells Blood Substit Immobil Biotechnol. 1994;22:701-708.
6. Schultz SC, Grady B, Cole F, Hamilton I, Burhop K, Malcolm DS. A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin. J Lab Clin Med. 1993;122:301-308.
7. Swan SK, Halstenson CE, Collins AJ, Colburn WA, Blue J, Przybelski RJ. Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. Am J Kidney Dis. 1995;26:918-923.
8. Przybelski RJ, Daily EK, Kisicki JC, Mattia-Goldberg C, Bounds MJ, Colburn WA. Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Crit Care Med. 1996;24: 1993-2000.
9. Baxter Healthcare Corporation. Baxter suspends European trauma trial for its hemoglobin therapeutic. Available at: http://www.prnewswire. com. Accessed June 2, 1998.
10. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
11. Farmer M, Ebeling A, Marshall T, Hauck W, Sun CS, White E, Long Z. Validation of virus inactivation by heat treatment in the manufacture of diaspirin crosslinked hemoglobin. Biomater Artif Cells Immobilization Biotechnol. 1992;20:429-433.
12. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH Stroke Scale. Arch Neurol. 1989;46:660-662.
13. Wade DT, Hewer RL. Functional abilities after stroke: measurement, natural history and prognosis. J Neurol Neurosurg Psychiatry. 1987;50: 177-182.
14. Saxena R, Wijnhoud AD, Man in 't Veld AJ, van den Meiracker AH, Boomsma F, Przybelski RJ, Koudstaal PJ. Effect of diaspirin cross-linked hemoglobin on endothelin-1 and blood pressure in acute ischemic stroke in man. J. Hypertens. 1998;16:1459-1465.
15. Barone FC, Willette RN, Yue TL, Feurestein G. Therapeutic effects of endothelin receptor antagonists in stroke. Neurol Res. 1985;17: 259-264.
16. Weitzberg E, Ahlborg G, Lundberg JM. Differences in vascular effects and removal of endothelin-1 in human lung, brain, and skeletal muscle. Clin Physiol. 1993;13:653-662.
17. del Zoppo GJ. Thrombolytic therapy in the treatment of stroke. Drugs. 1997;54(suppl 3):90-98.
18. Steinberg GK, Panahian N, Perez-Pinzon MA, Sun GH, Modi MW, Sepinwall J. Narrow temporal therapeutic window for NMDA antagonist protection against focal cerebral ischaemia. Neurobiol Dis. 1995;2: 109-118.
19. Baron JF, Berridge J, Brichant JF, Demeyere R, Lamy M, Larbuisson R, Cabot JJ, Parston M, Sinclair CJ, and the HemAssist™ Cardiac Surgery Trial Collaborative Group. The use of diaspirin cross-linked hemoglobin (DCLHb) as an alternative to blood transfusion in cardiac surgery patients following cardiopulmonary bypass: a pivotal efficacy trial. Anesthesiology. 1997;87:A217.